2020
DOI: 10.1038/s41416-020-0894-7
|View full text |Cite
|
Sign up to set email alerts
|

The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trials

Abstract: Background Immune-inflammatory biomarkers (IIBs) showed a prognostic relevance in patients with metastatic CRC (mCRC). We aimed at evaluating the prognostic power of a new comprehensive biomarker, the Pan-Immune-Inflammation Value (PIV), in patients with mCRC receiving first-line therapy. Methods In the present pooled-analysis, we included patients enrolled in the Valentino and TRIBE trials. PIV was calculated as: (neutrophil count × platelet count… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

12
163
0
1

Year Published

2020
2020
2024
2024

Publication Types

Select...
7

Relationship

1
6

Authors

Journals

citations
Cited by 172 publications
(218 citation statements)
references
References 20 publications
12
163
0
1
Order By: Relevance
“…More recently, the PIV has been proposed as a new and more potent predictor of clinical outcomes in cancer patients [ 26 ]. PIV showed a strong association with PFS and OS in patients with advanced colorectal cancer, and the prognostic value of the PIV was stronger than that of other well-established immune-inflammatory biomarkers (e.g., NLR).…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…More recently, the PIV has been proposed as a new and more potent predictor of clinical outcomes in cancer patients [ 26 ]. PIV showed a strong association with PFS and OS in patients with advanced colorectal cancer, and the prognostic value of the PIV was stronger than that of other well-established immune-inflammatory biomarkers (e.g., NLR).…”
Section: Discussionmentioning
confidence: 99%
“…Patients whose blood parameters were measured more than one month before treatment initiation, or after having received the first dose of the study treatment, were excluded from the analysis. From blood cell counts we calculated the following parameters: (a) PIV by multiplying neutrophil count (10 3 /mmc) by platelet count (10 3 /mmc) and monocyte count (10 3 /mmc) and, finally, dividing the result of this product by lymphocyte count (10 3 /mmc) [ 26 ]; (b) NLR by dividing neutrophil count (10 3 /mmc) by lymphocyte count (10 3 /mmc); (c) PLR by dividing platelet count (10 3 /mmc) by lymphocyte count (10 3 /mmc); (d) MLR by dividing monocyte (10 3 /mmc) by lymphocyte count (10 3 /mmc). The cut-off points to define patients with high or low PIV, NLR, PLR, or MLR were defined as median values of these parameters in the clinical cohort.…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“…However, two clinical studies 33,34 investigating the prognostic significance of the SII in CRC patients receiving neoadjuvant chemoradiotherapy showed that the SII was not an independent predictor for OS or DFS. In addition, a recent study 7 with 408 CRC patients reported that SII was not associated with OS or DFS in multivariate Cox regression analyses. Our study also assessed the prognostic value of the SII in patients with CRC, finding that the predictive ability as reflected by the…”
Section: Discussionmentioning
confidence: 98%
“…The systematic inflammatory response is mainly generated by innate immune cells and contributes to CRC induction and progression. 6,7 This inflammatory response can be reflected by a series of hematological indexes, including platelets, monocytes, basophils, 8 neutrophil-tolymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), platelet-to-lymphocyte ratio (PLR), and C-reactive protein (CRP)/prealbumin, 9 some of which are closely associated with survival in patients with CRC. 10,11 As the interplay between tumor, inflammation, and immunity depends on a complex network, 12,13 the clinical usefulness of a single biomarker is more or less limited by low predictive efficiency.…”
Section: Introductionmentioning
confidence: 99%